The FDA approved the first IV ferric carboxymaltose injection for iron deficiency in adults with heart failure to improve exercise capacity, according to a press release from American Regent.The IV iron injection (Injectafer, Daiichi Sankyo/American Regent) is approved for people with New York Heart Association class II/III HF, defined as patients with a slight or marked limitation of their
/PRNewswire/ CSL Vifor today announced that the U.S. Food and Drug Administration (FDA) has granted its partner American Regent, Inc., a Daiichi Sankyo.
This new indication for ferric carboxymaltose injection marks the first FDA approval of an intravenous iron replacement therapy for adult patients with heart failure, the company said.